Fruit fibre cut into short pieces, promoted for shedding toxic metals and slowing cancer spread. The human record is thin and lopsided: studies without a comparison group, by people connected to the maker, reported gains, while the two independent controlled trials found nothing. Harm is low: bowel symptoms, occasional itching. Evidence has not yet earned confidence in either direction. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Galectin-3 | Below 13 ng/mL for men, below 14 ng/mL for women | The proposed target; defines whether there is anything to block |
| Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | Sets clearance of the absorbed fraction and of mobilised metal |
| Whole blood lead | Below 1.0 µg/dL | The clearest objective target for detoxification use |
| Urine toxic-metals panel (arsenic, cadmium, lead, mercury) | Below the laboratory detection limit for each metal | Tracks what is actually being excreted |
| Ferritin | 50–125 ng/mL | Detects iron depletion from binder stacking |
| Serum zinc | 90–120 µg/dL | Detects the mineral loss that chelating agents typically cause |
| High-sensitivity C-reactive protein | Below 0.5 mg/L | Tracks the inflammation claim and flags confounders |
| Prostate-specific antigen | No established target; the doubling time is tracked against the individual's own pre-supplement trajectory | The only endpoint with human data in oncology use |
| Full blood count | Haemoglobin above 13.5 g/dL for men and above 12.5 g/dL for women | Catches anaemia from sustained mineral depletion |
Cadence: Bowel tolerance and body weight at 4 weeks; minerals, filtration rate and galectin-3 repeated at 12 weeks, then every 6 months while dosing continues; metal panels at the end of each 90-day round.